Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 17, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 11, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Adam Buckley, vice president of business development, will...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Sept. 12, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will provide a corporate...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 30, 2017) - Sci-B-Vac® is a third-generation hepatitis B vaccine, approved for use in Israel and 14 other...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 28, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that David Anderson, Ph.D., Chief Scientific Officer of VBI, will...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 15, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - July 27, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - July 11, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today its plans for a global Phase 3 clinical program for...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 28, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced the voting results from its annual general and special meeting...
-
CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 26, 2017) - VBI Vaccines, Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation...